1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium

• ChemBase ID: 1169
• Molecular Formular: C35H60N2O4++
• Molecular Mass: 572.8619
• Monoisotopic Mass: 572.45530841
• SMILES: [C@H]12[C@H]3[C@@H]([C@@]4([C@@H](CC3)C[C@@H]([C@H](C4)[N+]3(CCCCC3)C)OC(=O)C)C)CC[C@@]1([C@H]([C@H](C2)[N+]1(CCCCC1)C)OC(=O)C)C
• Canonical SMILES: CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]1(C)CCCCC1)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)[N+]1(C)CCCCC1)C
• InChI: InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
• InChIKey: GVEAYVLWDAFXET-XGHATYIMSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
• IUPAC Traditional name: 1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
• Brand Name: Mioblock; Pavulon
• Synonyms: Bromure de pancuronium [inn-french]; Bromuro de pancuronio [inn-spanish]; Pancuronium bromide; Pancuronium dibromide; Pancuronium

Database IDs

• CAS Number: 15500-66-0
• PubChem SID: 160964632; 46506118
• PubChem CID: 441289

CALCULATED PROPERTIES

JChem

• H Acceptors: 2
• H Donor: 0
• LogD (pH = 5.5): -3.2702475
• LogD (pH = 7.4): -3.2702475
• Log P: -3.2702475
• Molar Refractivity: 185.222 cm^3
• Polarizability: 65.27438 Å^3
• Polar Surface Area: 52.6 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 1.04
• LOG S: -8.32
• Solubility (Water): 3.08e-06 g/l

PROPERTIES

Physical Property

• Solubility: 500 mg/mL [MERCK INDEX (1996)]

DETAILS

DrugBank - DB01337

• Drug Groups: approved
• Description: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
• Indication: Used as a muscle relaxant during anesthesia and surgical procedures.
• Pharmacology: Pancuronium is a typical non-depolarising curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is, unlike suxamethonium, a non-depolarising agent, which means, that it causes no spontaneous depolarisations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration. Pancuronium has no hormonal activity. It exerts slight vagolytic activity (i.e. diminishing activity of the vagus nerve) and no ganglioplegic (i.e., blocking ganglions) activity.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic.
• Half Life: 1.5 to 2.7 hours.
• Protein Binding: 77 to 91%
• Distribution: * 241 to 280 mL/kg
• Clearance: * Plasma cl=1.1–1.9 mL/minute/kg
• External Links: Wikipedia